Finally, TSLP could be another target to inhibit Th2 responses in COVID-19 patients, as this molecule promotes allergic inflammation (40), and indeed, high levels of TSLP were observed in our cohort of COVID-19 but not pandemic influenza A(H1N1) subjects. Here, TSLP is linked to COVID-19.